Drug Trial Radar · NCT00000857
A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3
Last checked: Nov 20, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Not stated
Primary completion
Not stated
Study completion Jun 2001
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 1
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the tolerance and effectiveness of rhIL-12 in HIV-positive patients with CD4 cell counts less than 50 cells/mm3 versus 300-500 cells/mm3. This study will look at the ability of rhIL-12 to boost the immune system against HIV and HIV-associated bacterial infections in these patients. IL-12 is found naturally in the body and rhIL-12 is the commercially produced version. IL-12 may enhance anti-HIV immune system activity by increasing the number of cells that fight infection. IL-12 may also increase the body's ability to fight bacterial infections such as Mycobacterium avium complex (MAC).
Conditions
- HIV Infections
Interventions
Interleukin-12Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
UCLA CARE Center CRS
Los Angeles, California
USC CRS
Los Angeles, California
Stanford CRS
Palo Alto, California
Ucsf Aids Crs
San Francisco, California
Harbor-UCLA Med. Ctr. CRS
Torrance, California
Northwestern University CRS
Chicago, Illinois
Rush Univ. Med. Ctr. ACTG CRS
Chicago, Illinois
Weiss Memorial Hosp.
Chicago, Illinois
Indiana Univ. School of Medicine, Infectious Disease Research Clinic
Indianapolis, Indiana
Massachusetts General Hospital ACTG CRS
Boston, Massachusetts
Beth Israel Deaconess Med. Ctr., ACTG CRS
Boston, Massachusetts
NY Univ. HIV/AIDS CRS
New York, New York
Univ. of Rochester ACTG CRS
Rochester, New York
Unc Aids Crs
Chapel Hill, North Carolina
Hosp. of the Univ. of Pennsylvania CRS
Philadelphia, Pennsylvania
University of Washington AIDS CRS
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.